This article is more than 5 years old. Information may no longer be current.

EyeGate reports $8.4 million net loss in 2015

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported an $8.4 million net loss in 2015 compared with $1.6 million in 2014, according to a company press release.

Research and development expenses were reported at $2.7 million in 2015 compared with $0.5 million in 2014. The increase was attributed to clinical activity for EGP-437, the company’s leading drug candidate in clinical trials for treatment of anterior uveitis and macular edema.

Cash and cash equivalents were reported at $8.4 million in 2015 compared with $0.2 million in 2014. The increase was attributed to proceeds associated with the February 2015 initial public offering and August 2015 follow-on offering.